Informa PLC
Find out which market-moving events and catalysts to watch for during the upcoming Q1 Outlook Webinar - Key catalysts and their impact on pharma markets. During this webinar recording, industry analysts from Informa Pharma Intelligence present their data-based views on what’s in store for key drugs in early 2019. Discussion include important upcoming events related to these key drugs, their likelihood of phase/PDUFA review success and likelihood of approval, and an examination of the market significance of the drugs themselves.
Watch Now
Pharmtech
Speed and quality are key in pharmaceutical manufacturing. How can your equipment add value to your production process? Join the Lonza team to discover how the new Lonza Engine™ equipment portfolio is designed to support bioavailability enhancement, encapsulation and early-phase clinical development technologies.
Watch Now
Thermo Fisher Scientific
Osteosarcoma is the most common type of primary bone cancer affecting adolescents and children attributed to rapid bone growth and turnover with a peak incidence at 18 years old. it is a rare incurable and often fatal disease. The current osteosarcoma treatments include standard chemotherapy, limb salvage surgery or amputation. The 5-year relative survival rate is 70% for localized forms, however, metastasis is present in about one fifth to one-quarter of patients at diagnosis, which then contributes to a 5-year survival rate of around 20%. The survival statistics have remained constant with no advances in treatment options for decades highlighting the need for new therapeutic options.
Watch Now
pharmaintelligence
Understand important upcoming milestones that will impact the likelihood of drug approval or future sales potential for key therapies during a free webinar from Informa Pharma Intelligence, "Q4 Outlook Webinar - Key Catalysts and their Impact on Pharma Markets". During this important session, experts from the Datamonitor Healthcare team, part of the Commercial Strategy Suite at Pharma Intelligence, presented their insights into what to expect during the last quarter of the year.
Watch Now